What was the market valuation of the US allergy immunotherapy market in 2024?

The market valuation was $594.3 Million in 2024. Read More

What is the projected market valuation for the US allergy immunotherapy market by 2035?

The projected market valuation for 2035 is $1612.0 Million. Read More

What is the expected CAGR for the US allergy immunotherapy market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 9.5%. Read More

Which segment had the highest valuation in the US allergy immunotherapy market in 2024?

Sublingual Immunotherapy had the highest valuation, ranging from $250.0 Million to $700.0 Million. Read More

What are the key product segments in the US allergy immunotherapy market?

Key product segments include Allergen Extracts, Conventional Immunotherapy, and Biologics. Read More

Which patient type segment is projected to dominate the US allergy immunotherapy market?

The Adult patient type segment is projected to dominate, with a valuation range of $350.0 Million to $900.0 Million. Read More

Who are the leading companies in the US allergy immunotherapy market?

Key players include Allergan, Merck & Co, Aimmune Therapeutics, and Stallergenes Greer. Read More

What was the valuation range for Oral Immunotherapy in 2024?

The valuation range for Oral Immunotherapy was $144.3 Million to $362.0 Million. Read More

How does the market for Allergic Asthma compare to other indications in 2024?

The market for Allergic Asthma had a valuation range of $150.0 Million to $400.0 Million, indicating a substantial presence. Read More

US Allergy immunotherapy Market

Q: What indications are covered in the US allergy immunotherapy market?

Indications include Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies. Read More

ID: MRFR/Pharma/15188-HCR

100 Pages

Nidhi Mandole

Last Updated: April 24, 2026

US Allergy Immunotherapy Market Research Report By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies) and By Patient Type (Pediatric, Adult, Geriatric) - Growth & Industry Forecast 2025 To 2035

US Allergy immunotherapy Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Type (USD Million)
  1. 4.1.1 Subcutaneous Immunotherapy
  2. 4.1.2 Sublingual Immunotherapy
  3. 4.1.3 Oral Immunotherapy
2. 4.2 Chemicals and Materials, BY Product (USD Million)
  1. 4.2.1 Allergen Extracts
  2. 4.2.2 Conventional Immunotherapy
  3. 4.2.3 Biologics
3. 4.3 Chemicals and Materials, BY Indication (USD Million)
  1. 4.3.1 Allergic Rhinitis
  2. 4.3.2 Allergic Asthma
  3. 4.3.3 Atopic Dermatitis
  4. 4.3.4 Food Allergies
4. 4.4 Chemicals and Materials, BY Patient Type (USD Million)
  1. 4.4.1 Pediatric
  2. 4.4.2 Adult
  3. 4.4.3 Geriatric
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Allergan (IE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Aimmune Therapeutics (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Stallergenes Greer (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 DBV Technologies (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Boehringer Ingelheim (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bayer (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY PRODUCT
4. 6.4 US MARKET ANALYSIS BY INDICATION
5. 6.5 US MARKET ANALYSIS BY PATIENT TYPE
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY PRODUCT, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY PRODUCT, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY INDICATION, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY INDICATION, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY PATIENT TYPE, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY PRODUCT, 2025-2035 (USD Million)
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Type (USD Million, 2025-2035)

Subcutaneous Immunotherapy
Sublingual Immunotherapy
Oral Immunotherapy

Chemicals and Materials By Product (USD Million, 2025-2035)

Allergen Extracts
Conventional Immunotherapy
Biologics

Chemicals and Materials By Indication (USD Million, 2025-2035)

Allergic Rhinitis
Allergic Asthma
Atopic Dermatitis
Food Allergies

Chemicals and Materials By Patient Type (USD Million, 2025-2035)

Pediatric
Adult
Geriatric

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”